Skip to content

MDMA: all studies

Page 216 of 347: studies 2,151 to 2,160 of 3,461, newest first. Back to the MDMA overview

Research

PolDrugs 2025: results of the third edition of the nationwide study on psychoactive substance use in the context of psychiatry and harm reduction.

Frontiers in Psychiatry 2025 Julia Marek, Magdalena Domek-Gumprecht, Agata Macionga et al.

PolDrugs is a biennial epidemiological study aimed at analyzing patterns of mostly illicit psychoactive substance use in Poland in the context of psychiatry and harm reduction. This survey was held for the third time, and its results were compared to the last two editions. The survey was conducted as an online survey with 37 closed-ended single-choice questions and 3 multiple-choice questions....

Post-traumatic stress disorder in psychedelic research.

International review of neurobiology 2025 Tijmen Bostoen, Stephan Tap, Joost J. Breeksema et al. 1 citation

Post-Traumatic Stress Disorder (PTSD) is a severe psychiatric condition that develops after exposure to trauma such as combat, natural disasters, or assault. It is characterized by re-experiencing trauma, avoidance, hyperarousal, and negative alterations in cognition and mood. Since its formal inclusion in the Diagnostic and Statistical Manual of Mental Disorders (DSM)-III in 1980, PTSD has...

Biological treatments for co-occurring eating disorders and psychological trauma: a systematic review.

Frontiers in Psychiatry 2025 Ella van Beers, Irene de Vries, Caroline Planting et al. 2 citations

Many people with eating disorders report having experienced childhood maltreatment or a traumatic event prior to developing an eating disorder. Although many people with eating disorders have significant traumatic exposure or symptoms of post-traumatic stress disorder, very little research has examined the effects of combined treatments for this group. The purpose of this systematic review was...

Associations between psychedelic use and cannabis use disorder in a nationally representative sample.

Drug and Alcohol Dependence 2025 James M Zech, David B. Yaden, Grant Jones 9 citations

Cannabis Use Disorder (CUD) is an increasingly prevalent disorder affecting millions of Americans each year. Psychedelic compounds have recently been investigated for their therapeutic potential in treating substance use disorders, yet no prior work has examined the relationship between naturalistic use of specific psychedelic compounds and rates of disordered cannabis use. Using a nationally...

Psychedelic Medicine Exceptionalism.

The American Journal of Bioethics 2025 I. Glenn Cohen, Mason Marks 22 citations

Research on psychedelic medicines is experiencing a revival. Some clinicians, scientists, and ethicists believe that psychedelics are so different from other treatments that they warrant special consideration in how they are researched, regulated, commercialized, and administered. Others argue that psychedelic medicines show clinical potential, but they should be treated like other medical...

Is there a place for psychedelics in sports practice?

Acta Neuropsychiatrica 2025 Isabel Werle, Marina A. M. Portes, Leandro J Bertoglio 2 citations

Abstract Growing evidence suggests that psychedelic-assisted therapies can alleviate depression, anxiety, posttraumatic stress, and substance use disorder, offering relatively safe profiles, enhanced efficacy, and lasting effects after a few applications. Athletes often experience high levels of stress and pressure, making them susceptible to these psychiatric conditions. However, the effects...

Informed Consent in Psychedelic-Assisted Therapy.

Current Topics in Behavioral Neurosciences December 31, 2024 Mazdak M. Bradberry, Paul S. Appelbaum, Natalie Gukasyan 7 citations

Humans have long used classical serotonergic psychedelics, such as psilocybin, for a variety of purposes. Entactogens, such as methylenedioxymethamphetamine (MDMA), emerged during the twentieth century and have likewise seen use in a broad range of settings. Interest has arisen in the use of classical psychedelics and entactogens, together termed "psychedelics," for therapeutic purposes in...

The Australia story: Current status and future challenges for the clinical applications of psychedelics

British Journal of Pharmacology December 19, 2024 David Nutt, Peter Hunt, Anne Katrin Schlag et al. 21 citations

Abstract The past decade has seen a huge increase in clinical research with psychedelic drugs and 3,4‐methylenedioxymethamphetamine (MDMA), which have revealed great potential for treating mental health conditions. Given this progress in research, as well as the current unmet clinical need of millions of patients, in 2023, the Australian Therapeutic Goods Administration (TGA) approved the use...

DOI: 10.1111/bph.17398 (opens in new tab) Psilocybin Psychedelic therapy psychedelics Hallucinogens Entheogens +6

Exploring the regulatory framework of psychedelics in the US & Europe.

Asian Journal of Psychiatry December 1, 2024 Hitesh Kumar Behera, Ramesh Joga, Sravani Yerram et al.

Psychedelic drug therapy has gained prominence for its potential in treating various mental health conditions, including depression, post-traumatic stress disorder (PTSD), and anxiety. Psychedelic treatment differs from conventional psychiatric approaches in mode of action, legal status, and treatment approach. This work delves into the therapeutic potential, mechanisms, and regulatory...

Pattern of psychedelic substance use: a comparison between populations in Spain and South America using the Psychedelic Use Scale (PUS)

Current Psychology November 21, 2024 Jaime Rojas-Hernández, Lucas F Borkel, Domingo Jesús Quintana Hernández et al. 6 citations

Abstract Psychedelic use has increased in the last decade. However, it is unclear whether the cultural background of the consumers exerts any influence. The aim of the present study was to determine the pattern of psychedelic use in Spain and Spanish-speaking populations in South America and compare these consumption patterns to understand the use of these substances in two culturally distinct...